ATE343388T1 - Pde-v hemmer zur behandlung von morbus parkinson - Google Patents

Pde-v hemmer zur behandlung von morbus parkinson

Info

Publication number: ATE343388T1
Authority: AT; Austria
Prior art keywords: disease; parkinson; pde; inhibitor; treatment
Prior art date: 2000-04-19

Application number

AT01929063T

Other languages

English (en)

Inventor

H H Roylance

Original Assignee

Lilly Icos Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-19

Filing date

2001-04-17

Publication date

2006-11-15

2001-04-17 Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc

2006-11-15 Application granted granted Critical

2006-11-15 Publication of ATE343388T1 publication Critical patent/ATE343388T1/de

Links

208000018737 Parkinson disease Diseases 0.000 title abstract 2
239000002590 phosphodiesterase V inhibitor Substances 0.000 title 1
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 1
229940099471 Phosphodiesterase inhibitor Drugs 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 abstract 1
239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT01929063T 2000-04-19 2001-04-17 Pde-v hemmer zur behandlung von morbus parkinson ATE343388T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US19818000P	2000-04-19	2000-04-19

Publications (1)

Publication Number	Publication Date
ATE343388T1 true ATE343388T1 (de)	2006-11-15

Family

ID=22732318

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01929063T ATE343388T1 (de)	2000-04-19	2001-04-17	Pde-v hemmer zur behandlung von morbus parkinson

Country Status (9)

Country	Link
US (2)	US20020006926A1 (de)
EP (1)	EP1278522B1 (de)
JP (1)	JP2004500425A (de)
CN (1)	CN1436080A (de)
AT (1)	ATE343388T1 (de)
AU (2)	AU2001255849B8 (de)
CA (1)	CA2407031A1 (de)
DE (1)	DE60124085D1 (de)
WO (1)	WO2001078711A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10135815A1 (de) *	2001-07-23	2003-02-06	Bayer Ag	Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
WO2003020702A2 (en)	2001-08-31	2003-03-13	The Rockefeller University	Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
US8338420B1 (en)	2002-12-04	2012-12-25	Mitsubishi Tanabe Pharma Corporation	Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
US20050048573A1 (en) *	2003-02-03	2005-03-03	Plexxikon, Inc.	PDE5A crystal structure and uses
WO2006133261A2 (en)	2005-06-06	2006-12-14	Intra-Cellular Therapies, Inc.	Organic compounds
US20080194592A1 (en) *	2005-08-23	2008-08-14	Intra-Cellular Therapies, Inc.	Organic Compounds
EP1991214B1 (de) *	2006-02-21	2015-08-05	Teva Pharmaceutical Industries, Ltd.	Verwendung von rasagilin zur behandlung von multipler systematrophie
JP5453086B2 (ja) *	2006-06-06	2014-03-26	イントラ−セルラー・セラピーズ・インコーポレイテッド	有機化合物
TW200815045A (en) *	2006-06-29	2008-04-01	Jazz Pharmaceuticals Inc	Pharmaceutical compositions of ropinirole and methods of use thereof
US8841300B2 (en)	2006-10-02	2014-09-23	Jerry M. Held	Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
US9198924B2 (en) *	2006-11-13	2015-12-01	Intra-Cellular Therapies, Inc.	Organic compounds
EP2089034A4 (de)	2006-12-05	2010-07-28	Intra Cellular Therapies Inc	Neue verwendungszwecke
JP2010527928A (ja) *	2007-05-18	2010-08-19	ヴィヴァス・インコーポレイテッド	ホスホジエステラーゼ−５阻害剤を含む新規の組み合わせおよびそれらの使用
WO2009073210A1 (en) *	2007-12-06	2009-06-11	Intra-Cellular Therapies, Inc	Organic compounds
CN104370920A (zh)	2007-12-06	2015-02-25	武田药品工业株式会社	有机化合物
MX2010013393A (es)	2008-06-06	2011-06-21	Pharma Two B Ltd	Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson.
JP5778582B2 (ja)	2008-12-06	2015-09-16	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
EA201170772A1 (ru)	2008-12-06	2012-03-30	Интра-Селлулар Терапиз, Инк.	Органические соединения
BRPI0922700A2 (pt)	2008-12-06	2015-08-11	Intracellular Therapies Inc	Compostos orgânicos
MX2011005935A (es)	2008-12-06	2011-12-16	Intra Cellular Therapies Inc	Compuestos organicos.
EA201170771A1 (ru)	2008-12-06	2012-01-30	Интра-Селлулар Терапиз, Инк.	Органические соединения
WO2010065148A1 (en) *	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
EP2400970A4 (de)	2009-02-25	2012-07-18	Intra Cellular Therapies Inc	Pde-1-hemmer für augenleiden
US9468637B2 (en)	2009-05-13	2016-10-18	Intra-Cellular Therapies, Inc.	Organic compounds
JP6166534B2 (ja)	2009-08-05	2017-07-19	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	新規調節タンパク質および阻害剤
US9434730B2 (en)	2010-05-31	2016-09-06	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
US9371327B2 (en)	2010-05-31	2016-06-21	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
US9763948B2 (en)	2010-05-31	2017-09-19	Intra-Cellular Therapies, Inc.	PDE1 inhibitory compounds and methods
WO2012171016A1 (en) *	2011-06-10	2012-12-13	Intra-Cellular Therapies, Inc.	Organic compounds
US20150086481A1 (en) *	2011-07-28	2015-03-26	Memorial Sloan-Kettering Cancer Center	Diagnosis and treatment of parkinson's disease
WO2014127331A1 (en)	2013-02-17	2014-08-21	Intra-Cellular Therapies, Inc.	Novel uses
US9545406B2 (en)	2013-03-15	2017-01-17	Intra-Cellular Therapies, Inc.	Method of treating a CNS injury with a PDE1 inhibitor
US9598426B2 (en)	2013-03-15	2017-03-21	Intra-Cellular Therapies, Inc.	Organic compounds
WO2014172372A1 (en)	2013-04-15	2014-10-23	Northwestern University	Treatment for dopaminergic disorders
EP3091983B1 (de)	2014-01-08	2019-10-02	Intra-Cellular Therapies, Inc.	Pharmazeutische zusammensetzungen enthaltend einen pde-1-hemmer und einen pde-2-hemmer
US9884872B2 (en)	2014-06-20	2018-02-06	Intra-Cellular Therapies, Inc.	Organic compounds
US10285992B2 (en)	2014-08-07	2019-05-14	Intra-Cellular Therapies, Inc.	Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
DK3177627T3 (da)	2014-08-07	2019-10-21	Intra Cellular Therapies Inc	Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on-derivater med pde1-hæmmende aktivitet
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
IL292225B2 (en)	2014-09-17	2024-12-01	Intra Cellular Therapies Inc	Derivatives of 5,7,7-trimethyl-[2H]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one and pharmaceutical compositions comprising them.
US10300064B2 (en)	2014-12-06	2019-05-28	Intra-Cellular Therapies, Inc.	Organic compounds
AU2015357498B2 (en)	2014-12-06	2019-09-12	Intra-Cellular Therapies, Inc.	Organic compounds
US10682354B2 (en)	2016-03-28	2020-06-16	Intra-Cellular Therapies, Inc.	Compositions and methods
WO2017168174A1 (en)	2016-04-02	2017-10-05	N4 Pharma Uk Limited	New pharmaceutical forms of sildenafil
EP3970719A1 (de)	2016-09-12	2022-03-23	Intra-Cellular Therapies, Inc.	Pde1-inhibitor zur verwendung in einem verfahren zur behandlung oder prophylaxe von entzündungen und/oder einer entzündlichen krankheit oder störung
ES3035811T3 (en) *	2017-03-02	2025-09-09	Univ Amsterdam	Specific increase of dopamine synthesis through targeting of the guanylate cyclase 2c receptor in the treatment of parkinson's disease
JP7401442B2 (ja)	2018-01-31	2023-12-19	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規使用
US20210330736A1 (en) *	2018-09-05	2021-10-28	Universiteit Van Amsterdam	Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease
EP4025202A4 (de)	2019-09-03	2023-08-02	Intra-Cellular Therapies, Inc.	Neuartige verbindungen
US12364695B2 (en)	2020-06-02	2025-07-22	Intra-Cellular Therapies, Inc.	Methods of treating inflammatory disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4147789A (en) *	1974-03-14	1979-04-03	Sandoz Ltd.	6-Methyl-8-thiomethyl-ergolene derivatives
ATE199569T1 (de)	1993-05-27	2001-03-15	Univ Washington	Cyclisch gmp bindende cyclisch gmp spezifische phosphodiesterase materialien und verfahren.
GB9514465D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Chemical compounds
GB9401090D0 (en)	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
GB9514473D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Chemical compounds
EP0882718B1 (de) *	1995-12-28	2005-08-31	Fujisawa Pharmaceutical Co., Ltd.	Benzimidazolderivate
PL329875A1 (en)	1996-05-10	1999-04-12	Icos Corp	Derivatives of carbolin
CN1309561A (zh)	1997-05-29	2001-08-22	持田制药株式会社	勃起机能障碍治疗剂
WO1999021831A1 (en)	1997-10-27	1999-05-06	Fujisawa Pharmaceutical Co., Ltd.	Tricyclic compounds as cgmp-pde inhibitors
TR200001338T2 (tr)	1997-11-12	2000-08-21	Bayer Aktiengesellschaft	2-Fenil-ikameli imidazotriazinonlar
AU5067098A (en)	1997-11-26	1999-06-15	Mochida Pharmaceutical Co., Ltd.	Pyridocarbazole derivatives with cgmp-pde inhibitory activity
DE19752952A1 (de)	1997-11-28	1999-06-02	Merck Patent Gmbh	Thienopyrimidine
ZA9810766B (en)	1997-11-28	1999-05-25	Mochida Pharm Co Ltd	Novel compounds having cgmp-pde inhibitory activity
CA2314339C (en) *	1997-12-12	2009-09-08	Cell Pathways, Inc.	N-benzyl-3-indenylacetamide derivatives for treating neoplasia
EP1057819A4 (de)	1998-02-19	2003-02-05	Eisai Co Ltd	Phthalazinderivate und mittel gegen erektionstörungen
EP1371647B1 (de)	1998-04-20	2005-07-13	Pfizer Inc.	Pyridin-3-carbonsäurederivate und ihre Verwendung als Zwischenprodukte
WO1999054284A1 (en)	1998-04-20	1999-10-28	Fujisawa Pharmaceutical Co., Ltd.	Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
EP1218003A4 (de) *	1999-09-13	2004-02-11	David M Swope	Zusammenstellungen und methoden zur verminderung der neurologischer symptomatologie

2001
- 2001-04-17 CA CA002407031A patent/CA2407031A1/en not_active Abandoned
- 2001-04-17 WO PCT/US2001/040538 patent/WO2001078711A2/en not_active Ceased
- 2001-04-17 US US09/836,744 patent/US20020006926A1/en not_active Abandoned
- 2001-04-17 DE DE60124085T patent/DE60124085D1/de not_active Expired - Lifetime
- 2001-04-17 AU AU2001255849A patent/AU2001255849B8/en not_active Ceased
- 2001-04-17 AT AT01929063T patent/ATE343388T1/de not_active IP Right Cessation
- 2001-04-17 CN CN01811222A patent/CN1436080A/zh active Pending
- 2001-04-17 EP EP01929063A patent/EP1278522B1/de not_active Expired - Lifetime
- 2001-04-17 JP JP2001576012A patent/JP2004500425A/ja not_active Withdrawn
- 2001-04-17 AU AU5584901A patent/AU5584901A/xx active Pending
- 2001-11-21 US US09/989,672 patent/US6492371B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU5584901A (en)	2001-10-30
EP1278522A2 (de)	2003-01-29
US20020006926A1 (en)	2002-01-17
CN1436080A (zh)	2003-08-13
EP1278522B1 (de)	2006-10-25
WO2001078711A2 (en)	2001-10-25
US20020077274A1 (en)	2002-06-20
DE60124085D1 (de)	2006-12-07
WO2001078711A3 (en)	2002-07-04
CA2407031A1 (en)	2001-10-25
JP2004500425A (ja)	2004-01-08
AU2001255849B8 (en)	2006-04-27
US6492371B2 (en)	2002-12-10
AU2001255849B2 (en)	2005-12-22

Legal Events

Date	Code	Title	Description
2007-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60124085D1 (de)	2006-12-07	Pde-v hemmer zur behandlung von morbus parkinson
ATE389395T1 (de)	2008-04-15	Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
EA200201247A1 (ru)	2003-10-30	Соединения для лечения болезни альцгеймера
DE60124080D1 (de)	2006-12-07	Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
DE60112942D1 (de)	2005-09-29	Verbindungen zur behandlung der alzheimerischen krankheit
ATE355374T1 (de)	2006-03-15	Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200600294A1 (ru)	2006-08-25	[1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
GB0318447D0 (en)	2003-09-10	Therapeutic agents
EA200300528A1 (ru)	2003-10-30	1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
WO2002002520A3 (en)	2002-08-29	Compounds to treat alzheimer's disease
ATE254461T1 (de)	2003-12-15	Behandlung von augenschmerzen
EA200200716A1 (ru)	2003-02-27	Арилконденсированные азаполициклические соединения
EA200401114A2 (ru)	2005-02-24	Замещённые гидроксиэтиламины
EA200601212A1 (ru)	2006-10-27	Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
IL162515A0 (en)	2005-11-20	Substituted diketopiperazines as oxytocin antagonists
DE60142037D1 (de)	2010-06-17	Nasale verabreichung von metoclopramid zur behandlung der gastroparese
ATE464048T1 (de)	2010-04-15	Behandlung von alzheimer-krankheit und verwandten zuständen
ATE437855T1 (de)	2009-08-15	(4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
ATE315387T1 (de)	2006-02-15	Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
DE60330233D1 (de)	2010-01-07	Arsentherapie zur behandlung von autoimmunerkrankungen
DE59609219D1 (de)	2002-06-20	Verwendung von 1-hydroxy-2-pyridonen zur behandlung von schwer therapierbaren schleimhauterkrankungen
DE60108775T8 (de)	2006-08-24	Methode zur behandlung von schlaganfall
DE60310975D1 (de)	2007-02-15	Verwendung von epothilone zur behandlung hyperparathyreoidismus
ATE431348T1 (de)	2009-05-15	Thiaepothilone zur behandlung von krebserkrankungen
EA201001895A1 (ru)	2011-06-30	Пролекарства возбуждающих аминокислот